<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948428</url>
  </required_header>
  <id_info>
    <org_study_id>D94-3101-07</org_study_id>
    <nct_id>NCT00948428</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Parallel Group, Vehicle-Controlled Study to Determine the Clinical Equivalence of a Generic Imiquimod Cream, 5% and Aldara™ Cream in Subjects With Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At the end of the study, safety and efficacy outcome measures will be compared to determine&#xD;
      a) if dosing with Generic Imiquimod cream, 5% is therapeutically equivalent to the currently&#xD;
      marketed Aldara (imiquimod) cream, 5% and b) if both imiquimod 5% creams are superior in&#xD;
      comparison to the Vehicle cream.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A nationwide, multicenter, double-blind, vehicle-controlled parallel group comparison study&#xD;
      of a Generic Imiquimod cream, 5% (Actavis Mid-Atlantic LLC) and currently marketed Aldara&#xD;
      (imiquimod) cream, 5% (distributed by Graceway Pharmaceuticals, LLC) was conducted in&#xD;
      subjects with actinic keratoses (AKs) on the face and/or anterior scalp in order to evaluate&#xD;
      the therapeutic equivalence of these two active treatments and to establish superiority of&#xD;
      the efficacy of these two products over a Vehicle cream. Subjects were randomized to one of&#xD;
      three treatment groups on a 2:2:1 basis as follows: (1) Generic Imiquimod cream, 5%, (2)&#xD;
      Aldara (imiquimod) cream, 5%, and (3) Vehicle cream. The duration of treatment was 16 weeks&#xD;
      (± 7 days).&#xD;
&#xD;
      The primary efficacy endpoint was the proportion of subjects in each treatment group with&#xD;
      Complete Clearance (having no clinically visible actinic keratosis lesions in the 25 cm2&#xD;
      contiguous treatment area at the 8-week post-treatment visit) of AK lesions. The secondary&#xD;
      efficacy endpoints were the Partial Clearance rates, defined as the proportion of subjects&#xD;
      with at least a 75% reduction in the number of AK lesions counted at Baseline at the&#xD;
      end-of-treatment visit (Week 16, EOT) and at the 8 weeks post-treatment visit/test-of-cure&#xD;
      (Week 24, TOC), and the proportion of subjects with Complete Clearance of AK lesions at the&#xD;
      end-of-treatment (Week 16, EOT) visit.&#xD;
&#xD;
      A 90% Wald's confidence interval with Yate's continuity correction was constructed around the&#xD;
      difference between the proportions of subjects with Complete Clearance of AK lesions in the&#xD;
      active treatments (Generic Imiquimod minus Aldara) to evaluate therapeutic equivalence in the&#xD;
      primary efficacy analyses. Two-sided, continuity-corrected statistics were used to evaluate&#xD;
      the superiority of each active treatment's Complete Clearance rate over that of the Vehicle&#xD;
      treatment. The therapeutic comparability evaluations in the per-protocol (PP) population were&#xD;
      considered primary while those in the intent-to-treat (ITT) population were considered&#xD;
      supportive. The superiority comparisons in the ITT population were considered primary while&#xD;
      those in the PP population were considered supportive. If the 90% confidence interval (CI)&#xD;
      around the difference between the Generic Imiquimod and Aldara Complete Clearance rates in&#xD;
      the PP population were contained within the interval 0.20 to +0.20, and each of these rates&#xD;
      was greater than, and statistically different (p&lt;0.05) from, the Vehicle rate in the ITT&#xD;
      population, then Generic Imiquimod and Aldara were considered to be therapeutically&#xD;
      equivalent.&#xD;
&#xD;
      Secondary efficacy analyses were conducted on the proportion of subjects in each treatment&#xD;
      group with Complete Clearance of AK lesions at the Week 16, EOT visit as well as evaluation&#xD;
      of the Partial Clearance of AK lesions at both the EOT and TOC visits. The results at both&#xD;
      the EOT visit (Week 16) and those at 8 weeks post-treatment (Week 24, TOC) were statistically&#xD;
      analyzed by the same methods described for the primary efficacy variable.&#xD;
&#xD;
      Both EOT and TOC analyses were conducted in the ITT population. The TOC analysis was&#xD;
      conducted in the PP population and the EOT analysis was conducted in the EOT PP population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects in Each Treatment Group With Complete Clearance of AK Lesions at the Test of Cure Visit (Week 24)</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With at Least a 75% Reduction in the Number of AK Lesions From Baseline to End of Treatment (EOT) Visit (Week 16).</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With at Least a 75% Reduction in the Number of AK Lesions From Baseline to 8 Weeks Post Treatment (Test of Cure Visit).</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">462</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Generic Imiquimod</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>imiquimod cream, 5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aldara™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aldara™ (imiquimod) cream, 5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream (Actavis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imiquimod</intervention_name>
    <description>5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
    <arm_group_label>Generic Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldara™</intervention_name>
    <description>5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
    <arm_group_label>Aldara™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Cream</intervention_name>
    <description>Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
    <arm_group_label>Vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects were male or non-pregnant females, 18 years of age or older, in generally&#xD;
             good health. Females who were post-menopausal, surgically sterile or using a medically&#xD;
             acceptable form of birth control with a negative urine pregnancy test at the Baseline&#xD;
             visit.&#xD;
&#xD;
          -  Subjects provided written and verbal informed consent.&#xD;
&#xD;
          -  Subjects presented to the clinic with at least 4 but no more than 12 visible, discrete&#xD;
             nonhyperkeratotic, nonhypertrophic actinic keratosis lesions within a 25 cm2 Treatment&#xD;
             Area on the face and/or anterior scalp.&#xD;
&#xD;
          -  Subjects were willing and able to comply with study instructions and return to the&#xD;
             clinic for required visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who were lactating, or planning to become pregnant during the study.&#xD;
&#xD;
          -  Subjects had hyperkeratotic, hypertrophic or large mat-like AKs within the 25 cm2&#xD;
             Treatment Area.&#xD;
&#xD;
          -  Subjects who had the need or were planning to be exposed to artificial tanning devices&#xD;
             or excessive sunlight during the trial.&#xD;
&#xD;
          -  Subjects who were immunosuppressed (e.g., HIV, systemic malignancy, graft vs. host&#xD;
             disease, etc.).&#xD;
&#xD;
          -  Subjects who experienced an unsuccessful outcome from previous imiquimod therapy.&#xD;
&#xD;
          -  Subjects with known hypersensitivity or previous allergic reaction to any of the&#xD;
             active or inactive components of the study drugs.&#xD;
&#xD;
          -  Within 2 months: Facial and/or Anterior Scalp: laser resurfacing, photodynamic&#xD;
             therapy, chemical peels, dermabrasion, topical application of 5-FU, imiquimod,&#xD;
             diclofenac sodium or other treatments for AK or photodamage.&#xD;
&#xD;
          -  Subjects who used the following systemic, oral or topical therapies for the periods&#xD;
             specified prior to entry into the study:&#xD;
&#xD;
        Within 2 days: Topicals of any kind to the selected Treatment Area. Within 2 weeks: Facial&#xD;
        topical medications: corticosteroids, alpha- hydroxyacids (e.g., glycolic acid, lactic&#xD;
        acid, etc. greater than 5%), beta-hydroxyacid (salicylic acid greater than 2%), urea -&#xD;
        greater than 5% or prescription retinoids (e.g., tazarotene, adapalene, tretinoin) to the&#xD;
        face and/or anterior scalp.&#xD;
&#xD;
        Within 2 weeks: Cryotherapy to lesions adjacent to or within the 25 cm2 Treatment Area.&#xD;
&#xD;
        Within 4 weeks: Systemic steroid therapy: chemotherapeutic agents, psoralens,&#xD;
        immunotherapy, or retinoids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine M. Winslow, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Actavis Mid-Atlantic LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Research, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Surgery Medical Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherry Creek Research, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research Corp.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedaPhase, Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic, Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research Center of New York, Inc.</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Dermatology Consultants, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center, P.C.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital, Dermatopharmacology Division</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Knoxville, P.C.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce &amp; Associates, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 28, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <results_first_submitted>August 17, 2020</results_first_submitted>
  <results_first_submitted_qc>September 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2020</results_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>actinic keratoses</keyword>
  <keyword>imiquimod</keyword>
  <keyword>therapeutic equivalence</keyword>
  <keyword>bioequivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Generic Imiquimod</title>
          <description>Imiquimod cream, 5%&#xD;
Imiquimod: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
        </group>
        <group group_id="P2">
          <title>Aldara™</title>
          <description>Aldara™ (imiquimod) cream, 5%&#xD;
Aldara™: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Cream</title>
          <description>Vehicle cream (Actavis)&#xD;
Vehicle Cream: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent Illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Using Intent-to-Treat Population</population>
      <group_list>
        <group group_id="B1">
          <title>Generic Imiquimod</title>
          <description>Imiquimod cream, 5%&#xD;
Imiquimod: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
        </group>
        <group group_id="B2">
          <title>Aldara™</title>
          <description>Aldara™ (imiquimod) cream, 5%&#xD;
Aldara™: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Cream</title>
          <description>Vehicle cream (Actavis)&#xD;
Vehicle Cream: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="181"/>
            <count group_id="B2" value="179"/>
            <count group_id="B3" value="89"/>
            <count group_id="B4" value="449"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" spread="10.1"/>
                    <measurement group_id="B2" value="66.7" spread="10.4"/>
                    <measurement group_id="B3" value="66.7" spread="9.9"/>
                    <measurement group_id="B4" value="66.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="436"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="449"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects in Each Treatment Group With Complete Clearance of AK Lesions at the Test of Cure Visit (Week 24)</title>
        <time_frame>Week 24</time_frame>
        <population>Using Per-Protocol Population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Imiquimod</title>
            <description>Imiquimod cream, 5%&#xD;
Imiquimod: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aldara™</title>
            <description>Aldara™ (imiquimod) cream, 5%&#xD;
Aldara™: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Cream</title>
            <description>Vehicle cream (Actavis)&#xD;
Vehicle Cream: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects in Each Treatment Group With Complete Clearance of AK Lesions at the Test of Cure Visit (Week 24)</title>
          <population>Using Per-Protocol Population (PP)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% confidence interval around the difference between the Generic Imiquimod and Aldara Complete Clearance rates in the PP population were contained within the interval -0.20 to +0.20, and each of these rates was greater than, and statistically different (p&lt;0.05) from, the Vehicle rate in the ITT population, then Generic Imiquimod and Aldara were considered to be therapeutically equivalent</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.84</ci_lower_limit>
            <ci_upper_limit>9.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Based on Intent-to-Treat Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With at Least a 75% Reduction in the Number of AK Lesions From Baseline to End of Treatment (EOT) Visit (Week 16).</title>
        <time_frame>Week 16</time_frame>
        <population>Using the Intent-to-Treat Population Eighteen (18) ITT subjects from Site 15 are not included due to AK lesion counts not performed post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Imiquimod</title>
            <description>Imiquimod cream, 5%&#xD;
Imiquimod: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aldara™</title>
            <description>Aldara™ (imiquimod) cream, 5%&#xD;
Aldara™: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Cream</title>
            <description>Vehicle cream (Actavis)&#xD;
Vehicle Cream: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least a 75% Reduction in the Number of AK Lesions From Baseline to End of Treatment (EOT) Visit (Week 16).</title>
          <population>Using the Intent-to-Treat Population Eighteen (18) ITT subjects from Site 15 are not included due to AK lesion counts not performed post-baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% confidence interval around the difference between the Generic Imiquimod and Aldara Partial Clearance rates in the PP population were contained within the interval -0.20 to +0.20, then Generic Imiquimod and Aldara were considered to be therapeutically equivalent.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.11</ci_lower_limit>
            <ci_upper_limit>5.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With at Least a 75% Reduction in the Number of AK Lesions From Baseline to 8 Weeks Post Treatment (Test of Cure Visit).</title>
        <time_frame>Week 24</time_frame>
        <population>Using Intent-to-Treat population Eighteen (18) ITT subjects from Site 15 are not included due to AK lesion counts not performed post-baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Imiquimod</title>
            <description>Imiquimod cream, 5%&#xD;
Imiquimod: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aldara™</title>
            <description>Aldara™ (imiquimod) cream, 5%&#xD;
Aldara™: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Cream</title>
            <description>Vehicle cream (Actavis)&#xD;
Vehicle Cream: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least a 75% Reduction in the Number of AK Lesions From Baseline to 8 Weeks Post Treatment (Test of Cure Visit).</title>
          <population>Using Intent-to-Treat population Eighteen (18) ITT subjects from Site 15 are not included due to AK lesion counts not performed post-baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% confidence interval around the difference between the Generic Imiquimod and Aldara Complete Clearance rates in the ITT population were contained within the interval -0.20 to +0.20, then Generic Imiquimod and Aldara were considered to be therapeutically equivalent.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.92</ci_lower_limit>
            <ci_upper_limit>8.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Weeks</time_frame>
      <desc>Based on subjects in ITT</desc>
      <group_list>
        <group group_id="E1">
          <title>Generic Imiquimod</title>
          <description>Imiquimod cream, 5%&#xD;
Imiquimod: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
        </group>
        <group group_id="E2">
          <title>Aldara™</title>
          <description>Aldara™ (imiquimod) cream, 5%&#xD;
Aldara™: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Cream</title>
          <description>Vehicle cream (Actavis)&#xD;
Vehicle Cream: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Version 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Mixed hepatocellular cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery atenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Version 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Eye oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Stomach dicomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Application site alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Application site discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypertrigylceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Muskuloskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Mixed hepatocellular cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Transient acantholytic dermatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Blepharectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Varicose vein ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals USA, Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

